Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Tibet Duo Rui Pharmaceutical
301075
5
Chengda Pharmaceuticals
301201
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -35.88%36.78M | 38.71%19.29M | -71.26%4.93M | -2.49%16.5M | -142.11%-3.94M | 62.17%57.37M | 12.21%13.91M | 65.71%17.17M | 8.60%16.93M | 415.89%9.37M |
Net income from continuing operations | 48.77%30.88M | 87.50%9.84M | 4.06%7.48M | 12.09%5.96M | 153.46%7.59M | 205.25%20.75M | 37.84%5.25M | 97.53%7.19M | 514.32%5.32M | 297.43%2.99M |
Operating gains losses | -377.18%-984K | -303.56%-458K | 191.30%168K | 5.26%-54K | -272.51%-640K | 160.07%355K | 825.81%225K | 59.02%-184K | 61.22%-57K | 930.56%371K |
Depreciation and amortization | 44.20%11.89M | 45.49%3.63M | 44.87%2.74M | 44.97%2.81M | 41.10%2.71M | 1.05%8.24M | 25.59%2.49M | -6.57%1.89M | -7.14%1.94M | -6.79%1.92M |
Deferred tax | -0.57%-352K | 124.93%87K | -296.45%-332K | 305.61%220K | -419.05%-327K | 29.86%-350K | -160.38%-349K | 115.87%169K | -264.62%-107K | 18.18%-63K |
Other non cash items | 68.81%5.75M | 95.86%2.46M | 0.26%1.14M | 451.47%478K | 45.37%1.68M | -54.75%3.41M | -40.08%1.26M | -25.70%1.13M | -107.14%-136K | -42.42%1.16M |
Change In working capital | -183.47%-16.37M | -31.13%2.24M | -237.86%-7.94M | -36.77%5.57M | -1,000.83%-16.24M | 79.29%19.61M | 3.60%3.25M | 53.66%5.76M | -13.58%8.8M | 129.41%1.8M |
-Change in receivables | -106.42%-2.77M | -182.58%-5.94M | 67.56%-1.04M | -112.99%-2.24M | -70.45%6.46M | 432.09%43.1M | 174.35%7.19M | -670.98%-3.22M | 103.64%17.28M | 291.98%21.84M |
-Change in prepaid assets | ---- | ---- | -26.17%601K | 10.96%-601K | --0 | ---- | ---- | 76.57%814K | -31.07%-675K | 6.38%-44K |
-Change in payables and accrued expense | 35.02%-6.16M | 43.94%12.39M | -141.97%-2.45M | 158.61%3.82M | -14.41%-19.92M | -197.42%-9.48M | -26.03%8.61M | 433.70%5.84M | -71.21%-6.52M | -2,241.82%-17.41M |
-Change in other current assets | 66.42%-499K | -285.19%-104K | -104.73%-19K | -75.51%216K | 78.42%-592K | -231.74%-1.49M | -106.28%-27K | -67.00%402K | -45.22%882K | -28.78%-2.74M |
-Change in other current liabilities | -17.59%-3.99M | -16.15%-1.15M | -0.55%-730K | -1.24%-980K | -59.38%-1.13M | 19.97%-3.39M | -17.00%-991K | 44.07%-726K | 0.72%-968K | 36.75%-709K |
-Change in other working capital | 67.67%-2.95M | 74.12%-2.96M | -262.72%-4.29M | 548.70%5.35M | -221.20%-1.05M | -152.73%-9.12M | -869.38%-11.43M | -1.86%2.64M | -122.13%-1.19M | -88.77%868K |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -35.88%36.78M | 38.71%19.29M | -71.26%4.93M | -2.49%16.5M | -142.11%-3.94M | 62.17%57.37M | 12.21%13.91M | 65.71%17.17M | 8.60%16.93M | 415.89%9.37M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -149.06%-42.57M | -128.79%-24.84M | -149.43%-12.49M | -709.70%-3.26M | -140.39%-1.98M | -3,352.93%-17.09M | -5,022.17%-10.86M | -501,000.00%-5.01M | -161.04%-402K | -532.31%-822K |
Net PPE purchase and sale | -227.03%-5.99M | -102.08%-972K | 276.19%222K | -710.45%-3.26M | -140.88%-1.98M | -269.90%-1.83M | -126.89%-481K | -12,700.00%-126K | -161.04%-402K | -532.31%-822K |
Net business purchase and sale | -139.75%-36.59M | -130.03%-23.87M | ---- | ---- | ---- | ---15.26M | ---10.38M | ---- | ---- | ---- |
Net other investing changes | --7K | --0 | --0 | --3K | --4K | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -149.06%-42.57M | -128.79%-24.84M | -149.43%-12.49M | -709.70%-3.26M | -140.39%-1.98M | -3,352.93%-17.09M | -5,022.17%-10.86M | -501,000.00%-5.01M | -161.04%-402K | -532.31%-822K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 44.71%-9.12M | 1.31%-678K | -31.87%-811K | 83.74%-1.95M | -79.05%-5.67M | -23.49%-16.49M | 85.06%-687K | 60.88%-615K | 13.33%-12.02M | -147.40%-3.17M |
Net issuance payments of debt | 78.53%-3.05M | -0.94%-749K | -29.03%-889K | 93.04%-714K | 72.24%-693K | -31.20%-14.19M | -126.34%-742K | 89.60%-689K | 26.15%-10.26M | -136.26%-2.5M |
Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
Proceeds from stock option exercised by employees | 19.57%440K | 29.09%71K | 21.62%90K | 12.31%73K | 18.39%206K | 19.09%368K | 25.00%55K | 42.31%74K | 35.42%65K | 5.45%174K |
Net other financing activities | -143.62%-6.51M | --0 | ---12K | 28.09%-1.31M | -512.40%-5.19M | -214.47%-2.67M | --0 | --0 | -7,204.00%-1.83M | -133.33%-847K |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 44.71%-9.12M | 1.31%-678K | -31.87%-811K | 83.74%-1.95M | -79.05%-5.67M | -23.49%-16.49M | 85.06%-687K | 60.88%-615K | 13.33%-12.02M | -147.40%-3.17M |
Net cash flow | ||||||||||
Beginning cash position | 65.86%59.9M | -10.97%51.23M | 29.58%59.6M | 16.43%48.3M | 65.86%59.9M | 147.54%36.11M | 101.66%57.54M | 132.96%45.99M | 128.22%41.49M | 147.54%36.11M |
Current changes in cash | -162.66%-14.9M | -364.11%-6.23M | -172.51%-8.37M | 150.72%11.3M | -315.70%-11.59M | 10.49%23.78M | -68.87%2.36M | 31.35%11.54M | 188.04%4.51M | 49.72%5.38M |
End cash Position | -24.88%45M | -24.88%45M | -10.97%51.23M | 29.58%59.6M | 16.43%48.3M | 65.86%59.9M | 65.86%59.9M | 101.66%57.54M | 132.96%45.99M | 128.22%41.49M |
Free cash flow | -46.90%29.26M | 34.37%17.95M | -72.96%4.58M | -19.21%13.21M | -176.81%-6.49M | 60.27%55.1M | 10.19%13.36M | 67.66%16.95M | 7.00%16.35M | 369.40%8.44M |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |